GVR Report cover Europe Diabetic Foot Ulcer Treatment Market Size, Share & Trends Report

Europe Diabetic Foot Ulcer Treatment Market Size, Share & Trends Analysis Report By Treatment (Biologics, Wound Care Dressings), By Ulcer Type (Neuro-Ischemic, Ischemic, Neuropathic), And Segment Forecasts, 2022 - 2030

  • Report ID: GVR-4-68039-959-6
  • Number of Report Pages: 125
  • Format: PDF, Horizon Databook
  • Historical Range: 2018 - 2020
  • Forecast Period: 2022 - 2030 
  • Industry: Healthcare

Report Overview

The Europe diabetic foot ulcer treatment market size was valued at USD 1.45 billion in 2021 and is expected to expand at a compound annual growth rate (CAGR) of 5.4% from 2022 to 2030. Diabetes is one of the most common health conditions in geriatric patients in Europe and has affected nearly 19.3 million people aged 60-79, 11.3 million aged 40-59 years, and 1.7 million aged 20-39 years, in 2019. Germany accounted for the largest share of ~10.5% of the diabetic population in this region, followed by Portugal (~9.5%), and Cyprus (~9.0%). The prevalence rate of diabetes has stabilized in most of the region; however, it is increasing in Southern European countries and Central & Eastern European countries.

 U.K. diabetic foot ulcer treatment market size, by ulcer type, 2020 - 2030 (USD Million)

Factors, such as increasing obesity and physical inactivity are said to influence the rise in the diabetic population. Poorly-managed diabetes leads to blindness, kidney failure, cardiac arrest, liver failure, and limb amputation due to untreated foot ulcers. The global prevalence rate of foot ulcers in diabetic patients ranges between 4.0% and 10.0%, incidence rate lies between 1.0% and 4.1%. According to statistics published by the International Diabetes Federation, 10%–15% of diabetic patients may develop lesions once in their lifetime. Type 2 diabetic (T2D) patients are at a higher risk of developing DFUs compared to Type 1 Diabetic (T1D) patients.

DFUs are the leading cause of hospitalization among patients suffering from diabetes; a significant number of cases result in lower limb amputation. The prevalence of DFU varies significantly across continents. According to the International Journal of Diabetes and Endocrinology data, in 2016, North America reported the highest prevalence of DFU (13.0%), followed by Africa (7.2%), Asia (5.5%), and Europe (5.1%). The COVID-19 pandemic led to an increase in the prevalence of diabetes and fatal complications. Clinicians faced critical challenges to manage diabetic foot ulcers during the pandemic, due to limited access to laboratories, radiological testing, and reduced admission in care settings.

Despite the adoption of telehealth and telemedicine, diabetic foot ulcers needed personal attention and care. This surged the demand for DFU management tools in the market, leading to an increase in the supply by manufacturers. Companies like Smith and Nephew claimed that their revenues increased in the year 2020, due to the enormous sales of their leading DFU care products. In addition, studies published by the British Diabetic Association stated that, in England, nearly 5% of COVID-19 infected patients developed diabetes within 7 months post-discharge. Thus, the need for DFU treatment products increased at large- and small-scale hospitals, community clinics, surgery centers, nursing homes, and outpatient care settings.

Treatment Insights

The biologics segment dominated the regional market and accounted for the largest share of 34.65% of the overall revenue in 2021 and the segment is projected to expand further at the fastest CAGR during the forecast period. Biologics include growth factors, such as Vascular Endothelial Growth Factor (VEGF) and Platelet-Derived Growth Factor (PDGF), among others], stem cells, and other anti-diabetic drugs. These agents help reduce hyperglycemia, increase oxygenation & circulation, and repair lost tissues. Therefore, they are increasingly being used for the management of wounds in different stages and are considered to be ideal for DFU treatment. Wound care dressings held the second-largest share of the global revenue, followed by therapy devices and antibiotic medications, in 2021.

Wound care is further segmented into alginate dressings, hydro fiber dressings, foam dressings, film dressings, hydrocolloid dressings, surgical dressings, and hydrogel dressing. Foam dressing held the largest share in 2021. These dressings have been designed to absorb exudate and maintain moisture on the wound surface. Polyurethane foam dressings are applied directly or with an antimicrobial layer on the affected area and are then wrapped with a gauze or a bandage to provide compression. Alginate dressing, on the other hand, will register the highest CAGR from 2022 to 2030 due to the increasing use of alginate dressings in the treatment of DFUs. Alginate dressings are highly absorbent and help in maintaining a moist wound healing environment.

Ulcer Type Insights

The neuro-ischemic ulcers segment dominated the industry in 2021 and accounted for the largest share of more than 52.00% of the overall revenue, followed by the neuropathic and ischemic ulcer segments. The growth of this segment can be attributed to the number of risks associated with neuro-ischemic ulcers, such as infection, amputation, and death. Neuropathic ulcer affects nearly 35% of all ulcers, however, neuro-ischemia affects ~50% of the diabetic population. Sensorimotor and sympathetic diabetic neuropathy are major risk factors for DFU. Sensory neuropathy leads to loss of pain, pressure, and temperature sensation. In this case, trauma, or minor ulceration is perceived less or not at all. Motor neuropathy leads to muscle weakness and atrophy of the lower foot and ankle resulting in abnormal loading of the plantar aspect of the foot.

 Europe diabetic foot ulcer treatment market share, by ulcer type, 2021 (%)

Foot deformities, such as hammer toes and claw foot, develop secondary to motor neuropathy, leading to focal areas of increased pressure and the formation of calluses and ulcers. Sympathetic neuropathy results in reduced sweating, skin dryness with cracks and fissures, and increased blood flow to the foot with arteriovenous shunting. Hyperbaric oxygen therapy and sucrose octa sulfate dressing, are among the few highly researched treatments for neuro ischemic ulcers. Contact cast is considered the most effective option for treating neuro ischemic ulcers. Increased research and clinical studies are said to further enhance the growth of this segment. Treatment of DFU costs around, ~USD 779.50 million per annum in the U.K. and ~USD 10.21 billion per annum across Europe.

Regional Insights

Germany dominated the overall industry in 2021 and accounted for the largest share of28.00% of the total revenue. This growth was attributed to the presence of the highest diabetic patient population in the country. Globally, an estimated 463 million adults have diabetes out of which, 59 million are in Europe alone. In 2019, the diabetic prevalence rate had reached 15.3%, up from 12.2% in 2017. This leads to a total of ~9.5 million population suffering from diabetes out of which, 4.5 million cases go undiagnosed. Yearly ~6% of pregnant women in Germany suffer from gestational diabetes. The rising incidence of diabetes in this country has led to a sharp rise in the treatment for diabetic foot ulcers, leading to industry growth.

Other countries include the U.K., Italy, Spain, France, and Poland. According to the international diabetes federation, there were 747,600 cases of diabetes in Germany and 3.8 million people in the U.K. Around 10% of these diabetes patients develops foot ulcer in their lifetime. More than 7,000 diabetes amputation cases are reported in the country per year. Among diabetes hospital admissions in the U.K., 8.8% were related to amputation and ulcers. Around 25% of people with diabetes experience foot ulceration during their lifetime. Every year more than 22,000 people with diabetes mellitus lose a leg as a result of amputation.

Key Companies & Market Share Insights

Major industry participants are working to improve their service offerings by investing heavily in research and development to introduce newer and more efficient products in the market. Growing acquisitions, partnerships, expansions, and supportive government initiatives have led to strengthening their market position. For instance, in June 2022, Smith and Nephew, established an R&D and manufacturing unit in the U.K. to enhance its Advanced Wound Management segment. Some of the prominent players in the Europe diabetic foot ulcer treatment market include:

  • ConvaTec, Inc.

  • Acelity L.P., Inc.

  • 3M Healthcare

  • Coloplast Corp.

  • Smith & Nephew Plc

  • B Braun Melsungen AG

  • Medline Industries, Inc.

  • Organogenesis, Inc.

  • Molnlycke Health Care AB

  • Medtronic

Europe Diabetic Foot Ulcer Treatment Market Report Scope

Report Attribute


Market size value in 2022

USD 1.52 billion

Revenue forecast in 2030

USD 2.32 billion

Growth rate

CAGR of 5.4% from 2022 to 2030

Base year for estimation


Historical data

2018 - 2020

Forecast period

2022 - 2030

Quantitative units

Revenue in USD million/billion and CAGR from 2022 to 2030

Report coverage

Revenue forecast, company ranking, competitive landscape, growth factors, and trends

Segments covered

Treatment, ulcer type, region

Regional scope


Country scope

Germany; U.K.; Italy; Spain; France; Poland

Key companies profiled

ConvaTec, Inc.; Acelity L.P. Inc.; 3M Healthcare; Coloplast Corp.; Smith & Nephew Plc.; B Braun Melsungen AG; Medline Industries Inc.; Organogenesis, Inc.; Molnlycke Health Care AB; Medtronic

Customization scope

Free report customization (equivalent up to 8 analyst’s working days) with purchase. Addition or alteration to country, regional & segment scope

Pricing and purchase options

Avail customized purchase options to meet your exact research needs. Explore purchase options


Europe Diabetic Foot Ulcer Treatment Market Segmentation

This report forecasts revenue growth at the regional and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the Europe diabetic foot ulcer treatment market report based on treatment, ulcer type, and region:

Europe Diabetic Foot Ulcer Treatment Market Segmentation

  • Treatment Outlook (Revenue, USD Million, 2018 - 2030)

    • Wound Care Dressings

      • Alginate Dressings

      • Hydrofiber Dressings

      • Foam Dressings

      • Film Dressing

      • Hydrocolloid Dressings

      • Surgical Dressings

      • Hydrogel Dressings

    • Biologics

      • Growth Factors

      • Skin Grafts

    • Therapy Devices

      • Negative Pressure Wound Therapy

      • Ultrasound Therapy

    • Antibiotic Medications

    • Others

  • Ulcer Type Outlook (Revenue, USD Million, 2018 2030)

    • Neuropathic Ulcers

    • Ischemic Ulcers

    • Neuro-ischemic Ulcers

  • Regional Outlook (Revenue, USD Million, 2018 - 2030)

    • Germany

    • U.K.

    • Italy

    • Spain

    • France

    • Poland

Frequently Asked Questions About This Report

gvr icn


gvr icn

This FREE sample includes data points, ranging from trend analyses to estimates and forecasts. See for yourself.

gvr icn


We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities. Contact us now

Certified Icon

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.